OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
83 hedge funds and large institutions have $107M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.
115% more call options, than puts
Call options by funds: $2.25M | Put options by funds: $1.05M
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 83 → 83 (0)
57% less capital invested
Capital invested by funds: $247M → $107M (-$140M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.08M |
| 2 |
First Eagle Investment Management
New York
|
+$2.17M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.95M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.94M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$5.37M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$4.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.96M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.94M |
| 5 |
Morgan Stanley
New York
|
-$1.52M |
OMED Hedge Fund Activity: Q1 2016 in Review
83 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2016, worth a combined $107M — down 57% from $247M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OMED positions and 10 closed out — a net gain of 1 holder — while 34 added to existing stakes and 20 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.08M. The largest seller was Visium Asset Management, exiting entirely with an estimated $5.37M sold.
- 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $107M of OncoMed Pharmaceuticals, Inc. stock for Q1 2016, down 57% quarter-over-quarter.
- 11 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2016 and 10 closed out, a net change of +1 holder.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2016 was BVF Inc, an estimated $4.08M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2016 was Visium Asset Management, an estimated $5.37M sold.
Based on aggregated 13F filings for Q1 2016.